Overview
Location
United States
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 21, 2026 | ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT | An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratification, accelerate RTX-117 development, and create a shared foundation for next-gene... |
| Mar 2, 2026 | ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy | Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering A... |
| Nov 20, 2025 | ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone | BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institut... |
| Oct 13, 2025 | ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease | BRISBANE, Calif. , Oct. 13, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Dru... |
| Nov 26, 2024 | ReviR Therapeutics and Kennedy's Disease Association Partner to Advance Treatment for Rare Neuromuscular Disorder | BRISBANE, Calif., Nov. 26, 2024 /PRNewswire/ -- ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the K... |
| Jul 29, 2024 | ReviR Therapeutics Raises $30M in Series A Financing | ReviR Therapeutics, a Brisbane, CA-based AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, closed a $30m Series A financing. The round, which brought total raised so far to $54m,... |
| Jul 29, 2024 | Deals in brief: Hive Health raises USD 6.5 million, AgFunder VC closes fourth early-stage fund, ten China and India deals, and more | Hive Health raises USD 6.5 million in pre-Series A round Hive Health, a health insurance company based in Manila, has raised USD 6.5 million in a pre-Series A funding round. Key investors include Gentree Fund and Beenext, with participation... |
| Jul 27, 2024 | The Rise and Fall of Deals: A Closer Look at Recent Market Movements | In the world of business, deals can rise like the sun and fall like the night. Recent events in the market showcase this dynamic dance. From innovative funding rounds to failed acquisitions, the landscape is ever-changing. Let’s dive into t... |
| Jul 26, 2024 | ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders | BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a $30 ... |
Show more